Purpose of Review The impact of positive airway pressure (PAP) therapies on cardiovascular outcome in obstructive sleep apnea (OSA) and central sleep apnea (CSA) is currently under debate. The goal of this review is to critically analyze the current findings and discuss hypotheses on benefits or even harm in patients with heart failure (HF). Recent Findings While PAP sufficiently improves OSA, symptoms and cardiac parameters, the SAVE trial failed to show survival benefits. However, it was limited due to low adherence, non-sleepy population and maximal cardiac pre-treatment. SERVE-HF showed increased mortality in secondary analysis in patients with severe systolic HF with predominant CSA under adaptive servo-ventilation (ASV). Criticism of the trial emanated from high crossover, low compliance, use of older devices, and contradictory beneficial results in other studies. As sudden cardiac deaths was the reported main cause of mortality, influences of pre-medication and methods of pressure support on cardiac instability may have contributed to the pathogenesis. Summary OSA and CSA are main risk factors for poor outcome in cardiovascular disease. However, the effect of CPAP and ASVon cardiovascular comorbidities and prognosis requires further evaluation. Further insights from ongoing trials are urgently needed to clarify benefits and risk. . .
Current Sleep Medicine Reports – Springer Journals
Published: May 22, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera